EndoChoice

EndoChoice — the American equipment manufacturer founded in 2008 for performing endoscopy, detection of infections and pathologies for the doctors who are specializing in gastroenterology and including engaged in cancer therapy of a thick gut. As of September, 2016 EndoChoice works in 30 countries of the world.

Performance Indicators

2015

In 2015 financial year which came to the end on June 30 the 2016th calendar revenue of EndoChoice made $75 million that is 18% more, than the previous year.

2016: Boston Scientific buys EndoChoice for $210 million

At the end of September, 2016 the producer of the medical equipment Boston Scientific announced acquisition of EndoChoice for $210 million. Thanks to this transaction the buyer expands the business on release of endoscopic devices against the background of drop in sales of some products, The Wall Street Journal (WSJ) tells.

Under the terms of the agreement, Boston Scientific will pay own means $8 for each stock EndoChoice that is 90% more than a security price of the company by the time of closing of the exchange on the eve of the declaration of the transaction. After the statement for sale of EndoChoice of an action rose in price to those $8.

Thanks to EndoChoice purchase the Boston Scientific company will expand the business on release of endoscopic devices

Execute all formalities concerning EndoChoice acquisition, the Boston Scientific company plans in the fourth quarter 2016. The transaction will not affect income in 2017, but will allow to increase profit further, are sure of Boston Scientific.

In the publication of WSJ of September 27, 2016 it is said that in recent years Boston Scientific diversified the product portfolio for stimulation of the weakening sales in such important markets as pacemakers and the implanted defibrillators.

The division on release of the equipment for performing endoscopy of Boston Scientific which will include EndoChoice after closing of the transaction in the second quarter recorded 2016 revenue at the level of $361 million that is 11% more than an indicator of year prescription.^[1]

Notes